Clinic
Crossroads Treatment Center of Ashland, PSC
Crossroads Treatment Center of Ashland, PSC was paid $2.64M by Medicaid between Sep 2018 and Dec 2024, across 21 billing codes. Its largest line is H0020, Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) — 81% of everything it billed.
33Billing provider infoCROSSROADS TREATMENT CENTER OF ASHLAND, PSC
ASHLAND, KY 41101
ASHLAND, KY 41101
33aNPI1346745718assigned 03/28/2018
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$2.64M
24GClaims76,424
24DCodes billed21
24AFirst – last monthSep 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Kentucky
Rank by total paid#7 of 27
Median peer was paid$357K
This provider vs. median7.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCORMAC, RUPERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 652 | $12K | |
| 2019 | 23,854 | $209K | |
| 2020 | 23,059 | $559K | |
| 2021 | 9,565 | $491K | |
| 2022 | 5,487 | $372K | |
| 2023 | 7,536 | $519K | |
| 2024incomplete | 6,271 | $482K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 81% | 36,639 | 6,986 | $2.15M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 7.2% | 26,965 | 1,652 | $190K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 2.5% | 1,781 | 1,268 | $67K |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 1.9% | 461 | 328 | $50K |
| 99408 | 1.3% | 2,235 | 234 | $34K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 739 | 556 | $33K |
| H0033 | Oral medication administration, direct observation | 1.2% | 444 | 313 | $30K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 1,228 | 937 | $29K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 1,734 | 491 | $25K |
| 82075 | <1% | 1,088 | 792 | $10K | |
| 99441 | <1% | 1,501 | 481 | $7K | |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 209 | 122 | $6K |
9 more codes
| T2023 | Targeted case management; per month | <1% | 19 | $3K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 699 | $3K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 230 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 89 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $454.61 |
| 99406 | <1% | 129 | $449.14 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 20 | $343.29 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 122 | $310.70 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 79 | $156.59 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCORMAC, RUPERT (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.